Adrenergic β3 Receptors
The adrenergic β3 receptor (β3-adrenoceptor) is a member of the adrenergic receptor group of G-protein-coupled receptors that also includes α1A, α1B, α1D, α2A, α2B, α2C, β1 and β2. They are located primarily in the small intestine, adipose tissue and vascular endothelium.
Adrenergic β3 Receptor Agonists |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 0948 | BRL 37344, sodium salt |
| β3 agonist | |
| 1134 | CGP 12177 hydrochloride |
| β3 partial agonist. β1/β2 antagonist | |
| 1499 | CL 316243 disodium salt |
| Highly selective β3 agonist | |
| 2197 | L-755,507 |
| Very potent and selective β3 partial agonist | |
| 7070 | Mirabegron |
| Potent and selective β3 agonist | |
| 3986 | SR 58611A hydrochloride |
| β3 agonist; displays anxiolytic and antidepressant effects | |
Adrenergic β3 Receptor Antagonists |
|
| Cat. No. | Product Name / Activity |
| 2760 | L-748,337 |
| Selective β3 antagonist | |
| 1511 | SR 59230A hydrochloride |
| Potent and selective β3 antagonist | |
The adrenergic β3 receptor (β3-adrenoceptor) is a member of the adrenergic receptor group of G-protein-coupled receptors that also includes α1A, α1B, α1D, α2A, α2B, α2C, β1 and β2. They are located primarily in the small intestine, adipose tissue and vascular endothelium where they are involved in lipolysis, glucose uptake, cardio-inhibition and relaxation of colon, esophagus and bladder. The human β3 receptor gene has been localized to chromosome 8 (8p12-8p11.1).
External sources of pharmacological information for Adrenergic β3 Receptors :
Literature for Adrenergic β3 Receptors
Tocris offers the following scientific literature for Adrenergic β3 Receptors to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Written by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDF